Stocks rallied Tuesday after U.S. President Donald Trump announced a ceasefire in the Israel-Iran conflict, although the ...

Hims & Hers Health Inc. (HIMS) rebounded 4.38% in after-hours trading Monday, partially clawing back losses after the stock ...

Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...

First, the stock has sliced through two support levels. Shares broke through their 50-day moving average on Monday for the ...

Novo Nordisk abruptly ended its partnership with Hims & Hers after the Danish drugmaker accused the telehealth company of ...

The loss of its ability to sell Wegovy is a significant hit to Hims & Hers' business. The massive drop today in its stock ...

The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent ...

Hims & Hers Health shares tumbled 33% in intraday trading Monday after Novo Nordisk said it is pulling out of its partnership ...

Hims & Hers Health, Inc. (HIMS) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might ...

Many companies have failed to disrupt the complicated U.S. healthcare market. Hims & Hers (NYSE: HIMS) may finally be succeeding in cracking the code. The online telehealth platform focuses on ...